Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

2.075 +0.095 (+4.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
From Mainz BioMed NV
Via GlobeNewswire
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Expands into Switzerland with labor team w
Partnership to Launch DNA-Based Colorectal Cancer Screening Test 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Stock Split
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% 
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS